FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1868909663> ?p ?o ?g. }

• W1868909663 startingPage "2294" @default.
• W1868909663 abstract "Background: Cases of severe pulmonary hypertension (PH) have been reported in chronic myelogenous leukemia (CML) patients treated with Src/ABL tyrosine kinase inhibitor dasatinib. Methods: The present report summarizes the clinical characteristics and outcomes of dasatinib-associated PH cases from the French PH Registry. Results: Between 1st January 2008 and 30th September 2010, 11 patients with either a diagnosis of CML and/or a treatment with imatinib, dasatinib or nilotinib were identified corresponding to 2 prevalent imatinib-treated CML patients previously reported by our group and who developed PH prior to treatment with imatinib (Souza et al, Thorax 2006:61:736) and 9 incident patients who were all exposed to dasatinib at the time of PH diagnosis. The lowest estimate of incident PH occurring in patients exposed to dasatinib was 9/2,900 (0.31%), as compared with no incident case reported with imatinib or nilotibib in the same period. A relationship was suspected between dasatinib exposure and occurrence of pre-capillary PH and dasatinib was stopped in all patients immediately after PH diagnosis. Clinical, functional and haemodynamic improvements were observed within 4 months of dasatinib discontinuation, in all patients. However, complete clinical and hemodynamic recovery was not observed in most patients and only 4 patients reached normal pulmonary vascular resistance Conclusion: Dasatinib therapy may promote severe pre-capillary PH, suggesting a direct and specific effect of dasatinib." @default.
• W1868909663 created "2016-06-24" @default.
• W1868909663 creator A5019426997 @default.
• W1868909663 creator A5022727833 @default.
• W1868909663 creator A5023226226 @default.
• W1868909663 creator A5029745665 @default.
• W1868909663 creator A5031477165 @default.
• W1868909663 creator A5032218282 @default.
• W1868909663 creator A5034854080 @default.
• W1868909663 creator A5038824744 @default.
• W1868909663 creator A5059392358 @default.
• W1868909663 creator A5062137164 @default.
• W1868909663 creator A5063103135 @default.
• W1868909663 creator A5068222850 @default.
• W1868909663 creator A5069745915 @default.
• W1868909663 creator A5084112278 @default.
• W1868909663 creator A5084905217 @default.
• W1868909663 creator A5085643508 @default.
• W1868909663 creator A5086312824 @default.
• W1868909663 creator A5089300668 @default.
• W1868909663 creator A5090333661 @default.
• W1868909663 date "2011-09-01" @default.
• W1868909663 modified "2023-09-24" @default.
• W1868909663 title "Pulmonary hypertension in patients treated with Src/Abl kinase inhibitor dasatinib" @default.
• W1868909663 hasPublicationYear "2011" @default.
• W1868909663 type Work @default.
• W1868909663 sameAs 1868909663 @default.
• W1868909663 citedByCount "0" @default.
• W1868909663 crossrefType "journal-article" @default.
• W1868909663 hasAuthorship W1868909663A5019426997 @default.
• W1868909663 hasAuthorship W1868909663A5022727833 @default.
• W1868909663 hasAuthorship W1868909663A5023226226 @default.
• W1868909663 hasAuthorship W1868909663A5029745665 @default.
• W1868909663 hasAuthorship W1868909663A5031477165 @default.
• W1868909663 hasAuthorship W1868909663A5032218282 @default.
• W1868909663 hasAuthorship W1868909663A5034854080 @default.
• W1868909663 hasAuthorship W1868909663A5038824744 @default.
• W1868909663 hasAuthorship W1868909663A5059392358 @default.
• W1868909663 hasAuthorship W1868909663A5062137164 @default.
• W1868909663 hasAuthorship W1868909663A5063103135 @default.
• W1868909663 hasAuthorship W1868909663A5068222850 @default.
• W1868909663 hasAuthorship W1868909663A5069745915 @default.
• W1868909663 hasAuthorship W1868909663A5084112278 @default.
• W1868909663 hasAuthorship W1868909663A5084905217 @default.
• W1868909663 hasAuthorship W1868909663A5085643508 @default.
• W1868909663 hasAuthorship W1868909663A5086312824 @default.
• W1868909663 hasAuthorship W1868909663A5089300668 @default.
• W1868909663 hasAuthorship W1868909663A5090333661 @default.
• W1868909663 hasConcept C108636557 @default.
• W1868909663 hasConcept C121608353 @default.
• W1868909663 hasConcept C126322002 @default.
• W1868909663 hasConcept C170493617 @default.
• W1868909663 hasConcept C2776960273 @default.
• W1868909663 hasConcept C2777413986 @default.
• W1868909663 hasConcept C2777583451 @default.
• W1868909663 hasConcept C2778461978 @default.
• W1868909663 hasConcept C2778715236 @default.
• W1868909663 hasConcept C2778729363 @default.
• W1868909663 hasConcept C2778820342 @default.
• W1868909663 hasConcept C2779536868 @default.
• W1868909663 hasConcept C42362537 @default.
• W1868909663 hasConcept C71924100 @default.
• W1868909663 hasConcept C90924648 @default.
• W1868909663 hasConceptScore W1868909663C108636557 @default.
• W1868909663 hasConceptScore W1868909663C121608353 @default.
• W1868909663 hasConceptScore W1868909663C126322002 @default.
• W1868909663 hasConceptScore W1868909663C170493617 @default.
• W1868909663 hasConceptScore W1868909663C2776960273 @default.
• W1868909663 hasConceptScore W1868909663C2777413986 @default.
• W1868909663 hasConceptScore W1868909663C2777583451 @default.
• W1868909663 hasConceptScore W1868909663C2778461978 @default.
• W1868909663 hasConceptScore W1868909663C2778715236 @default.
• W1868909663 hasConceptScore W1868909663C2778729363 @default.
• W1868909663 hasConceptScore W1868909663C2778820342 @default.
• W1868909663 hasConceptScore W1868909663C2779536868 @default.
• W1868909663 hasConceptScore W1868909663C42362537 @default.
• W1868909663 hasConceptScore W1868909663C71924100 @default.
• W1868909663 hasConceptScore W1868909663C90924648 @default.
• W1868909663 hasOpenAccess W1868909663 @default.
• W1868909663 hasRelatedWork W2077663268 @default.
• W1868909663 hasRelatedWork W2354266325 @default.
• W1868909663 hasRelatedWork W2394724078 @default.
• W1868909663 hasRelatedWork W2558133906 @default.
• W1868909663 hasRelatedWork W2560206501 @default.
• W1868909663 hasRelatedWork W2560411042 @default.
• W1868909663 hasRelatedWork W2561523883 @default.
• W1868909663 hasRelatedWork W2564629313 @default.
• W1868909663 hasRelatedWork W2577770511 @default.
• W1868909663 hasRelatedWork W2579023027 @default.
• W1868909663 hasRelatedWork W2599551048 @default.
• W1868909663 hasRelatedWork W2600212366 @default.
• W1868909663 hasRelatedWork W2604779344 @default.
• W1868909663 hasRelatedWork W2801418858 @default.
• W1868909663 hasRelatedWork W2889475285 @default.
• W1868909663 hasRelatedWork W2966084920 @default.
• W1868909663 hasRelatedWork W2980225292 @default.
• W1868909663 hasRelatedWork W2993534021 @default.
• W1868909663 hasRelatedWork W2994371102 @default.
• W1868909663 hasRelatedWork W3123960236 @default.

• next